“NLX-101 for the Treatment of Rett Syndrome”

In Clinical Development, Featured on App, Orphan Drug Congress by Freya Smale

MarkVarneyPresImage
Mark Varney of Neurolixis  joined us at World Orphan Drug Congress USA 2015 to present about ‘ NLX-101 for the Treatment of Rett Syndrome’. 

Download the presentation now to learn about:

  • Rett Syndrome: Key Facts
  • Pleiotropy in Rett Syndrome
  • NLX-101: A selective 5-HT 1A  receptor “biased agonist” 
…and much more!
Get your copy here!
To find out more about  NLX-101 as a treatment of Rett Syndrome , join us at World Orphan Drug Congress USA 2016 April 20-22 in Washington, DC.